FR
Contact
EquipeExpertise
ActualitésClassements & distinctionsPublications & conférences
À propos de nousCarrièreContact
de|fr|it|en
DEITEN
Contact
EquipeExpertise
ActualitésClassements & distinctionsPublications & conférences
À propos de nousCarrièreContact
de|fr|it|en
DEITEN
de|fr|it|en
Bâle Berne Binningen China Desk Genève Gstaad Japan Desk Lausanne Lugano Sion ZurichBâle Berne Binningen China Desk Genève Gstaad Japan Desk Lausanne Lugano Sion Zurich
  • Equipe
  • Expertise
  • Actualités
  • Classements & distinctions
  • Publications & conférences
  • À propos de nous
  • Carrière
  • Contact
  • LinkedIn
  • Instagram
Imprint–Terms of use–Privacy notice–Cookie policy–
© 2026
  • Equipe
  • Expertise
  • Actualités
  • Classements & distinctions
  • Publications & conférences
  • À propos de nous
  • Carrière
  • Contact
  • LinkedIn
  • Instagram
Imprint–Terms of use–Privacy notice–Cookie policy–
© 2026

Transactions & cas

Dr. Nicolas Mosimann
  • Kellerhals Carrard advises eps Holding GmbH on the combination of the eps Event Group and NÜSSLI (Switzerland) Ltd.Kellerhals Carrard advises eps Holding GmbH on the combination of the eps Event Group and NÜSSLI (Switzerland) Ltd.27 août 2026
  • Kellerhals Carrard advises on the sale of a majority stake in Hipp Technology GroupKellerhals Carrard advises on the sale of a majority stake in Hipp Technology Group24 mars 2026
  • Kellerhals Carrard berät Eigentümer der Tretor AG bei Transaktion mit Pictet Alternative AdvisorsKellerhals Carrard berät Eigentümer der Tretor AG bei Transaktion mit Pictet Alternative Advisors11 mars 2026
  • Deal Ticker: Kellerhals Carrard advised on the sale of LakeraDeal Ticker: Kellerhals Carrard advised on the sale of Lakera6 novembre 2025
  • Deal Ticker: Kellerhals Carrard advised Sofinnova Partners and Earlybird Venture Capital on financing round with HAYA TherapeuticsDeal Ticker: Kellerhals Carrard advised Sofinnova Partners and Earlybird Venture Capital on financing round with HAYA Therapeutics15 mai 2025
  • Deal Ticker: Kellerhals Carrard Advised MoonLake Immunotherapeutics on Debt Financing with Hercules Capital, Inc.Deal Ticker: Kellerhals Carrard Advised MoonLake Immunotherapeutics on Debt Financing with Hercules Capital, Inc.4 avril 2025
  • Kellerhals Carrard Advises on the Sale of Baccinex S.A. to Adragos PharmaKellerhals Carrard Advises on the Sale of Baccinex S.A. to Adragos Pharma3 décembre 2024
  • Deal Ticker: Kellerhals Carrard Advised on Acquisition of Majority Stake in Walter Meier (Fertigungslösungen) AGDeal Ticker: Kellerhals Carrard Advised on Acquisition of Majority Stake in Walter Meier (Fertigungslösungen) AG27 mai 2024
  • Deal Ticker: Novartis hands over the Life-Science-Park Rhine Valley to GETEC Switzerland.Deal Ticker: Novartis hands over the Life-Science-Park Rhine Valley to GETEC Switzerland.23 août 2023
  • Deal Ticker: Kellerhals Carrard acted as lead counsel in connection with Biognosys’ strategic partnership with Bruker CorporationDeal Ticker: Kellerhals Carrard acted as lead counsel in connection with Biognosys’ strategic partnership with Bruker Corporation6 janvier 2023
  • Deal Ticker: Kellerhals Carrard advised BVF on the purchase agreement with NLS Pharmaceutics.Deal Ticker: Kellerhals Carrard advised BVF on the purchase agreement with NLS Pharmaceutics.19 décembre 2022
  • MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp.6 avril 2022